| Followers | 45 |
| Posts | 4322 |
| Boards Moderated | 0 |
| Alias Born | 12/16/2019 |
Friday, January 29, 2021 9:07:16 AM
The article is great news.
Read the entire article and you will see that it is still a great vaccine and will continue to save lives and spare many hospitalization.
What every everyone does;
Don't freaking panic sell this stock.
$JNJ
Read the entire article and you will see that it is still a great vaccine and will continue to save lives and spare many hospitalization.
What every everyone does;
Don't freaking panic sell this stock.
$JNJ
“Always give your best, never get discouraged, never be petty; always remember, others may hate you, but those who hate you don't win unless you hate them, and then you destroy yourself.”
Richard Nixon
Recent JNJ News
- Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference • Business Wire • 04/21/2026 08:22:00 PM
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026 • Business Wire • 04/21/2026 11:45:00 AM
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care • GlobeNewswire Inc. • 04/16/2026 03:00:00 PM
- Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference • Business Wire • 04/15/2026 08:11:00 PM
- Johnson & Johnson Beats Q1 Expectations, Lifts 2026 Outlook • IH Market News • 04/14/2026 12:42:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2026 11:35:25 AM
- Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1% • Business Wire • 04/14/2026 10:21:00 AM
- Johnson & Johnson reports Q1 2026 results, raises 2026 outlook • Business Wire • 04/14/2026 10:20:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/13/2026 03:15:34 PM
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision • Business Wire • 04/10/2026 12:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • InvestorsHub NewsWire • 04/09/2026 01:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- Johnson & Johnson introduces VARIPULSE Pro in Europe after CE Mark clearance • IH Market News • 04/07/2026 02:12:35 PM
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe • Business Wire • 04/07/2026 12:00:00 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- J&J reports one-year ICOTYDE psoriasis trial results show sustained efficacy • IH Market News • 03/30/2026 09:32:48 AM
- ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis • PR Newswire (US) • 03/28/2026 02:00:00 PM
- Nanobiotix Shares Surge After Report of Possible Johnson & Johnson Takeover Interest • IH Market News • 03/25/2026 02:00:48 PM
- FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide • PR Newswire (US) • 03/18/2026 11:49:00 AM
- Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 03/13/2026 04:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 01:31:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 12:39:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 12:37:30 AM
